Vitamin D and thyroid disease: To D or not to D?

European Journal of Clinical Nutrition

Volumn 69, Issue 3, 2015, Pages 291-296

  Muscogiuri, G ^a   Tirabassi, G ^b   Bizzaro, G ^c   Orio, F ^d   Paschou, S A ^e   Vryonidou, A ^e   Balercia, G ^b   Shoenfeld, Y ^c,f   Colao, A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c SHEBA MEDICAL CENTER   (Israel)

^d UNIVERSITY HOSPITAL SAN GIOVANNI DI DIO E RUGGI D ARAGONA   (Italy)

^e RED CROSS HOSPITAL   (Greece)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; COLECALCIFEROL; CYCLOSPORIN; ERGOCALCIFEROL; VITAMIN D; VITAMIN;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE THYROIDITIS; CANCER GROWTH; CARCINOGENESIS; DENDRITIC CELL; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE COURSE; HISTOCHEMISTRY; HUMAN; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; THYROID CANCER; THYROID FUNCTION; VITAMIN D DEFICIENCY; VITAMIN INTAKE; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION; BLOOD; COMPLICATION; GRAVES DISEASE; HASHIMOTO DISEASE; THYROID DISEASES; THYROID NEOPLASMS;

DIETARY SUPPLEMENTS; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; THYROID DISEASES; THYROID NEOPLASMS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84924604397     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2014.265     Document Type: Review

References (68)

1. Basit S. Vitamin D in health and disease: a literature review. Br J Biomed Sci 2013; 70: 161-172.
2. Chapuy MC, Schott AM, Garnero P, Hans D, Delmas PD, Meunier PJ. Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter: EPIDOS Study Group. J Clin Endocrinol Metab 1996; 81: 1129-1133.
3. Lips P, Hosking D, Lippuner K, Norquist JM, Wehren L, Maalouf G et al. The prevalence of vitamin D de ficiency amongst women with osteoporosis: an international epidemiological investigation. J Intern Med 2006; 260: 245-254.
4. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006; 81: 353-373.
5. Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004; 158: 531-537.
6. Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among free-living healthy young adults. Am J Med 2002; 112: 659-662.
7. EURODIAB Study Group. Vitamin D supplement in early childhood and risk for type I (insulin-dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group. Diabetologia 1999; 42: 51-54.
8. Song Y, Wang L, Pittas AG, Del Gobbo LC, Zhang C, Manson JE et al. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care 2013; 36: 1422-1428.
9. Lopez ER, Zwermann O, Segni M, Meyer G, Reincke M, Seissler J et al. A promoter polymorphism of the CYP27B1 gene is associated with Addison's disease, Hashimoto's thyroiditis, Graves' disease and type 1 diabetes mellitus in Germans. Eur J Endocrinol 2004; 151: 193-197.
10. Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2006; 114: 577-583.
11. McDonnell DP, Pike JW, O'Malley BW. The vitamin D receptor: a primitive steroid receptor related to thyroid hormone receptor. J Steroid Biochem 1988; 30: 41-46.
12. Lamberg-Allardt C, Valtonen E, Polojärvi M, Stewen P. Characterization of a 1,25-dihydroxy-vitamin D3 receptor in FRTL-5 cells. Evidence for an inhibitory effect of 1,25-dihydroxy-vitamin D3 on thyrotropin-induced iodide uptake. Mol Cell Endocrinol 1991; 81: 25-31.
13. Berg JP, Liane KM, Bjørhovde SB, Bjøro T, Torjesen PA, Haug E. Vitamin D receptor binding and biological effects of cholecalciferol analogues in rat thyroid cells. J Steroid Biochem Mol Biol 1994; 50: 145-150.
14. Törnquist K, Lamberg-Allardt C. Systemic effects of 1,25-dihydroxyvitamin D3 on the pituitary-hypothalamic axis in rats. Acta Endocrinol (Copenh) 1987; 115: 225-228.
15. Tamer G, Arik S, Tamer I, Coksert D. Relative vitamin D insufficiency in Hashimoto's thyroiditis. Thyroid 2011; 21: 891-896.
16. Yasuda T, Okamoto Y, Hamada N, Miyashita K, Takahara M, Sakamoto F et al. Serum vitamin D levels are decreased and associated with thyroid volume in female patients with newly onset Graves' disease. Endocrine 2012; 42: 739-741.
17. Clinckspoor I, Verlinden L, Mathieu C, Bouillon R, Verstuyf A, Decallonne B. Vitamin D in thyroid tumorigenesis and development. Prog Histochem Cytochem 2013; 48: 65-98.
18. Baeke F, Etten EV, Overbergh L, Mathieu C. Vitamin D3 and the immune system: maintaining the balance in health and disease. Nutr Res Rev 2007; 20: 106-118.
19. Karthaus N, van Spriel AB, Looman MW, Chen S, Spilgies LM, Lieben L et al. Vitamin D controls murine and human plasmacytoid dendritic cell function. J Invest Dermatol 2014; 134: 1255-1264.
20. Mathieu C. Vitamin D and the immune system: getting it right. IBMS BoneKEy 2011; 8: 178-186.
21. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010; 10: 482-496.
22. Inukai Y, Momobayashi A, Sugawara N, Aso Y. Changes in expression of T-helper (Th) 1-and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease. Eur J Endocrinol 2007; 156: 623-630.
23. Misharin A, Hewison M, Chen CR, Lagishetty V, Aliesky HA, Mizutori Y et al. Vitamin D deficiency modulates Graves' hyperthyroidism induced in BALB/c mice by thyrotropin receptor immunization. Endocrinology 2009; 150: 1051-1060.
24. Kivity S, Agmon-Levin N, Zisappl M, Shapira Y, Nagy EV, Dankó K et al. Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol 2011; 8: 243-247.
25. Shin DY, Kim KJ, Kim D, Hwang S, Lee EJ. Low serum vitamin D is associated with anti-thyroid peroxidase antibody in autoimmune thyroiditis. Yonsei Med J 2014; 55: 476-481.
26. Choi YM, Kim WG, Kim TY, Bae SJ, Kim HK, Jang EK et al. Low levels of serum vitamin D3 are associated with autoimmune thyroid disease in pre-menopausal women. Thyroid 2014; 24: 655-661.
27. Chailurkit LO, Aekplakorn W, Ongphiphadhanakul B. High vitamin D status in younger individuals is associated with low circulating thyrotropin. Thyroid 2013; 23: 25-30.
28. Goswami R, Marwaha RK, Gupta N, Tandon N, Sreenivas V, Tomar N et al. Prevalence of vitamin D deficiency and its relationships with thyroid autoimmunity in Asian Indians: a community-based survey. Br J Nutr 2009; 102: 382-386.
29. Effraimidis G, Badenhoop K, Tijssen JG, Wiersinga WM. Vitamin D deficiency is not associated with early stages of thyroid autoimmunity. Eur J Endocrinol 2012; 167: 43-48.
30. Mackawy AM, Al-Ayed BM, Al-Rashidi BM. Vitamin D deficiency and its association with thyroid disease. Int J Health Sci 2013; 7: 267-275.
31. Zhang Q, Wang Z, Sun M, Cao M, Zhu Z, Fu Q et al. Association of high vitamin d status with low circulating thyroid-stimulating hormone independent of thyroid hormone levels in middle-aged and elderly males. Int J Endocrinol 2014; 2014: 631819.
32. Feng M, Li H, Chen SF, Li WF, Zhang FB. Polymorphisms in the vitamin D receptor gene and risk of autoimmune thyroid disease: a meta-analysis. Endocrine 2013; 43: 318-326.
33. Pani MA, Regulla K, Segni M, Krause M, Hofmann S, Hufner M et al. Vitamin D 1α-hydroxylase (CYP1α) polymorphism in Graves' disease, Hashimoto's thyroiditis and type 1 diabetes mellitus. Eur J Endocrinol 2002; 146: 777-781.
34. Khadzkou K, Buchwald P, Westin G, Dralle H, Akerström G, Hellman P. 25-hydroxyvitamin D3 1alpha-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. J Histochem Cytochem 2006; 54: 355-361.
35. Clinckspoor I, Hauben E, Verlinden L, Van den Bruel A, Vanwalleghem L, Vander Poorten V et al. Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors. J Histochem Cytochem 2012; 60: 502-511.
36. Somjen D, Grafi-Cohen M, Posner GH, Sharon O, Kraiem Z, Stern N. Vitamin D less-calcemic analog modulates the expression of estrogen receptors, vitamin D receptor and 1α-hydroxylase 25-hydroxy vitamin D in human thyroid cancer cell lines. J Steroid Biochem Mol Biol 2013; 136: 80-82.
37. Clinckspoor I, Verlinden L, Overbergh L, Korch C, Bouillon R, Mathieu C et al. 1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer. J Steroid Biochem Mol Biol 2011; 124: 1-9.
38. Liu W, Asa SL, Fantus IG, Walfish PG, Ezzat S. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and-independent pathways. Am J Pathol 2002; 160: 511-519.
39. Suzuki S, Takenoshita S, Furukawa H, Tsuchiya A. Antineoplastic activity of 1,25 (OH)2D3 and its analogue 22-oxacalcitriol against human anaplastic thyroid carcinoma cell lines in vitro. Int J Mol Med 1999; 4: 611-614.
40. Bennett RG, Wakeley SE, Hamel FG, High RR, Korch C, Goldner WS. Gene expression of vitamin D metabolic enzymes at baseline and in response to vitamin D treatment in thyroid cancer cell lines. Oncology 2012; 83: 264-272.
41. Dackiw AP, Ezzat S, Huang P, Liu W, Asa SL. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology 2004; 145: 5840-5846.
42. Akagi T, Luong QT, Gui D, Said J, Selektar J, Yung A et al. Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells. Br J Cancer 2008; 99: 781-788.
43. Peleg S, Abruzzese RV, Cooper CW, Gagel RF. Down-regulation of calcitonin gene transcription by vitamin D requires two widely separated enhancer sequences. Mol Endocrinol 1993; 7: 999-1008.
44. Zabel M, Dietel M. Calcitriol decreases calcitonin secretion from a human medullary carcinoma cell line via specific receptor action. Acta Endocrinol (Copenh) 1991; 125: 299-304.
45. Zabel M, Flig K, Gebarowska E, Surdyk-Zasada J. The effect of calcitriol and its analogues on proliferation and hormone expression in cultured cells of thyroid medullary carcinomas. Folia Morphol (Warsz) 2003; 62: 463-465.
46. Zabel M, Gebarowska E, Drag-Zalesińska M, Wysocka T. Effect of calcitriol on proliferation of TT cells and on expression of calcitonin gene. Folia Histochem Cytobiol 2002; 40: 187-188.
47. Baier R, Grauer A, Lazaretti-Castro M, Ziegler R, Raue F. Differential effects of 1,25-dihydroxyvitamin D3 on cell proliferation and calcitonin gene expression. Endocrinology 1994; 135: 2006-2011.
48. Cote GJ, Rogers DG, Huang ES, Gagel RF. The effect of 1,25-dihydroxyvitamin D3 treatment on calcitonin and calcitonin gene-related peptide mRNA levels in cultured human thyroid C-cells. Biochem Biophys Res Commun 1987; 149: 239-243.
49. Liu W, Asa SL, Ezzat S. 1alpha,25-Dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness. Mol Endocrinol 2005; 19: 2349-2357.
50. Roskies M, Dolev Y, Caglar D, Hier MP, Mlynarek A, Majdan A et al. Vitamin D deficiency as a potentially modifiable risk factor for thyroid cancer. J Otolaryngol Head Neck Surg 2012; 41: 160-163.
51. Sahin M, Uc¸an B, Giniş Z, Topaloʇlu O, Güngüneş A, Bozkurt NC¸ et al. Vitamin D3 levels and insulin resistance in papillary thyroid cancer patients. Med Oncol 2013; 30: 589.
52. Stepien T, Krupinski R, Sopinski J, Kuzdak K, Komorowski J, Lawnicka H et al. Decreased 1-25 dihydroxyvitamin D3 concentration in peripheral blood serum of patients with thyroid cancer. Arch Med Res 2010; 41: 190-194.
53. Jonklaas J, Danielsen M, Wang H. A pilot study of serum selenium, vitamin D, and thyrotropin concentrations in patients with thyroid cancer. Thyroid 2013; 23: 1079-1086.
54. Laney N, Meza J, Lyden E, Erickson J, Treude K, Goldner W. The prevalence of vitamin D deficiency is similar between thyroid nodule and thyroid cancer patients. Int J Endocrinol 2010; 2010: 805716.
55. Mack WJ, Preston-Martin S, Bernstein L, Qian D. Lifestyle and other risk factors for thyroid cancer in Los Angeles County females. Ann Epidemiol 2002; 12: 395-401.
56. Ron E, Kleinerman RA, Boice Jr JD, LiVolsi VA, Flannery JT, Fraumeni Jr JF. A population-based case-control study of thyroid cancer. J Natl Cancer Inst 1987; 79: 1-12.
57. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al. Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-1930.
58. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. In: Ross AC, Taylor CL, Yaktine AL, Del Valle HB (eds). Dietary Reference Intakes for Calcium and Vitamin D. National Academies Press (US): Washington (DC), 2011.
59. Agmon-Levin N, Theodor E, Segal RM, Shoenfeld Y. Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol 2013; 45: 256-266.
60. Fournier C, Gepner P, Sadouk M, Charreire J. In vivo beneficial effects of cyclosporin A and 1,25-dihydroxyvitamin D3 on the induction of experimental autoimmune thyroiditis. Clin Immunol Immunopathol 1990; 54: 53-63.
61. Chen W, Lin H, Wang M. Immune intervention effects on the induction of experimental autoimmune thyroiditis. J Huazhong Univ Sci Technolog Med Sci 2002; 22: 343-345.
62. Robien K, Oppeneer SJ, Kelly JA, Hamilton-Reeves JM. Drug-vitamin D interactions: a systematic review of the literature. Nutr Clin Pract 2013; 28: 194-208.
63. Brannon PM, Yetley EA, Bailey RL, Picciano MF. Summary of roundtable discussion on vitamin D research needs. Am J Clin Nutr 2008; 88: 587-592.
64. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013; 369: 1991-2000.
65. Hollis BW. Comparison of commercially available (125)I-based RIA methods for the determination of circulating 25-hydroxyvitamin D. Clin Chem 2000; 46: 1657-1661.
66. Gilbertson TJ, Stryd RP. High-performance liquid chromatographic assay for 25-hydroxyvitamin D3 in serum. Clin Chem 1977; 23: 1700-1704.
67. Saenger AK, Laha TJ, Bremner DE, Sadrzadeh SM. Quantification of serum 25-hydroxyvitamin D(2) and D(3) using HPLC-tandem mass spectrometry and examination of reference intervals for diagnosis of vitamin D de ficiency. Am J Clin Pathol 2006; 125: 914-920.
68. Tsugawa N, Suhara Y, Kamao M, Okano T. Determination of 25-hydroxyvitamin D in human plasma using high-performance liquid chromatography - tandem mass spectrometry. Anal Chem 2005; 77: 3001-3007.